Volunteer

Thank you for your interest in the SPARX3 study. We are actively recruiting participants for this ongoing study. Below is more information for volunteering in SPARX3.

Approximately 29 sites will enroll participants: 27 sites that cover all geographic regions of the USA and 2 sites in Canada. All sites will have a collaboration between movement disorders and exercise specialists. The sites have extensive experience conducting studies involving exercise and people with Parkinson's disease (PD).

What is SPARX3 about?

SPARX3 (NCT04284436) is a Phase 3 multi-site, randomized study of endurance treadmill exercise on changes in the signs and symptoms of PD. The goal of SPARX3 is to test whether the progression of the signs of PD is decreased in people who have not initiated medication for PD when they perform endurance treadmill exercise. 370 persons diagnosed with PD who have not yet initiated medication, age 40-80 years, will be randomly assigned to either moderate-intensity or high-intensity exercise training.

What are the research study procedures?

First, you will complete a telephone screening followed by two in-person screening visits to confirm that you meet the criteria to participate in the study. These visits consist of physical and memory/thinking assessments, a blood draw, a questionnaire to screen for depression, and a brain scan (DaTscan) that helps confirm the diagnosis of PD. If you are eligible to participate in this study, you will then complete 7 additional assessment visits over the course of the 24 months, which consist of more physical and memory/thinking assessments, questionnaires, blood draws, exercise tests, and one additional brain scan. You will be randomized (like flipping a coin) to one of two exercise groups. You will be asked to exercise at a specific rate/intensity 4 days per week for approximately 30 min.

Who qualifies to volunteer in the SPARX3 study?

We are seeking individuals with PD who are willing to take part in a regular treadmill exercise program 4x/week for 18 months and participate in study visits periodically for 24 months.

Volunteers must be:

    • 40-80 years old

    • Diagnosed with PD within the last 3 years

    • Not yet taking medications for PD symptoms

    • Not planning to start medications for PD symptoms in the next 6 months

    • Not currently participating in a structured exercise program

What will volunteers be asked to do?

  • Physical and cognitive assessments

  • Blood draws at the start and end of the study

  • Imaging scans (DaTscan)

  • 18 months of treadmill exercise

  • Regularly scheduled in-person study visits over 24 months

During this study, participants will be encouraged:

  • To refrain from enrolling in other studies or interventions that could affect your motor symptoms or aerobic fitness, but can continue to engage in their usual physical activities.

  • To refrain from enrolling in other studies that require a DaTscan™ SPECT imaging procedure as part of the study activities, with the exception of the PPMI2.0 study.

  • To refrain from taking dopaminergic medication unless medically necessary for the duration of the study

If you think that you may be eligible for participation please use the map and links below to find and contact the nearest clinical site for SPARX3.

If you need assistance with your participation in the SPARX3 study contact Elizabeth Skender by email or call at 309-922-7254.

PARTICIPATING SITES

Clinical Sites Contacts

Alabama

University of Alabama at Birmingham

Contact: Sydney Burdette

Phone: 678-200-0624

Principal Investigator: Christopher Hurt, PhD

California

University of California, San Francisco

Contact: Corinna Conroy

Phone: 415-502-2960


Principal Investigator: Carlie Tanner

Principal Investigator: Nijee Luthra

Colorado

University of Colorado - Denver

Contact: Katherine Balfany

Phone: 303-724-9101

Principal Investigator: Cory Christiansen, PhD

Florida

University of Florida

Contact: Amanda Fessenden

Phone: 352-733-2421

Principal Investigator: Demetra Christou, PhD

Georgia

Emory University

Contact: Joe Nocera

Phone: 404-321-6111

Principal Investigator: Joe Nocera, PhD

Morehouse School of Medicine

Contact: Parkinsons Study Email

Phone: 404-756-5053

Principal Investigator: Chantale Branson, MD


Illinois

Northwestern University

Contact: Garett Griffith

Phone: 708-703-2591

Principal Investigator: Cynthia Poon, PhD

Rush University Medical Center

Contact: Olga Solonowicz

Phone: 312-563-5564

Principal Investigator: Mitra Afshari, MD

Iowa

Iowa State University

Contact: Elizabeth Stegemoller

Phone: 515-294-5966

Principal Investigator: Elizabeth Stegemoller, PhD

Louisiana

Louisiana State University & Louisiana State University Health Science Center

Contact: Jan Hondzinski

Phone: 225-578-9144

Principal Investigator: Jan Hondzinski, PhD

Massachusetts

Boston University (Charles River Campus)

Contact: Michael Stevenson

Phone: 617-638-7747

Principal Investigator: Terry Ellis, PhD

Principal Investigator: Ludy Shih, MD

Michigan

University of Michigan

Contact: Julia Silverman

Phone: 631-356-9361

Contact: Jacob Haus, PhD

Phone: 734-647-2790


Principal Investigator: Jacob Haus, PhD

Minnesota

University of Minnesota

Contact: Kristin Garland

Phone: 612-505-6574

Principal Investigator: Colum MacKinnon, PhD

Missouri

Washington University St. Louis

Contact: Martha Hessler

Phone: 314-286-1478


Principal Investigator: Gammon Earhart, PhD

New York

New York University Langone Health

Contact: Martina Romain

Phone: 929-455-5312

Principal Investigator: Patrick Drummond, MD


Columbia University Medical Center

Contact: Corey Landis

Phone: 212-305-1647


Principal Investigator: Ashwini Rao, EdD

Ohio

Ohio Health

Contact: Kitra Hunter

Phone: 614-566-1262

Principal Investigator: David Hinkle


University of Cincinnati

Contact: Jessica Marchbank

Phone: 513-558-4811

Principal Investigator: Alberto Espay, MD


Cleveland Clinic

Contact: MacKenzie Dunlap

Phone: 216-444-7474

Principal Investigator: Jay Alberts, PhD


University Hospitals/Kent State University

Contact: Elisar Khawam

Phone: 216-844-1800

Principal Investigator: Angela Ridgel, PhD

Oregon

Oregon Health & Science University

Contact: Graham Harker

Phone: 503-418-2601

Principal Investigator: Martina Mancini, PhD

Pennsylvania

University of Pennsylvania

Contact: Marcela Pavón

Contact: Whitney Hartstone

Phone: 215-829-7725

Principal Investigator: Andres Diek Acost Madiedo, MD


University of Pittsburgh

Contact: Kathy Betts

Phone: 412-383-6736

Principal Investigator: Deborah Josbeno, PhD

Texas

University of Texas Medical Brand

Contact: Summer Chapman

Phone: 409-266-9666

Principal Investigator: Blake Rasmussen, PhD

Utah

University of Utah and Intermountain Healthcare

Contact: Genevieve Olivier

Contact: Erin Suttman

Phone: 801-587-3181

Principal Investigator: Lee Dibble, PhD

Virginia

University of Virginia

Contact: Lauren Miller

Phone: 434-982-6599

Principal Investigator: Art Weltman, PhD

Canada

University of Alberta

Contact: Krista Nelles

Phone: 780-248-2043

Principal Investigator: Richard Camicioli, MD

Principal Investigator: Kelvin Jones, PhD

Hounds of SPARX3

Meet our friendly canine team assisting us find volunteers! Thank you for visiting the SPARX3 website.